APA

Takao T., Kobayashi Y., Kuroda J., Omoto A., Nishimura T., Kamitsuji Y., Fukiya E., Nakamura C., Kimura S. & Yoshikawa T. (20050118). Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. : American journal of hematology.

Chicago

Takao Toshitatsu, Kobayashi Yutaka, Kuroda Junya, Omoto Atsusi, Nishimura Tomoko, Kamitsuji Yuri, Fukiya Etsuko, Nakamura Chie, Kimura Shinya and Yoshikawa Toshikazu. 20050118. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. : American journal of hematology.

Harvard

Takao T., Kobayashi Y., Kuroda J., Omoto A., Nishimura T., Kamitsuji Y., Fukiya E., Nakamura C., Kimura S. and Yoshikawa T. (20050118). Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. : American journal of hematology.

MLA

Takao Toshitatsu, Kobayashi Yutaka, Kuroda Junya, Omoto Atsusi, Nishimura Tomoko, Kamitsuji Yuri, Fukiya Etsuko, Nakamura Chie, Kimura Shinya and Yoshikawa Toshikazu. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. : American journal of hematology. 20050118.